FIGURE 5 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies

Association of B7-H3 expression with key driver mutations. Alteration frequency of TP53 mutations (A), RB1 mutations (B), KRAS mutations (C), MYC amplifications (D) of across 10 different cancer types with high and low B7-H3 expression. **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.